Cost-effectiveness of budesonide controlled ileal release (CIR) capsules as maintenance therapy versus no maintenance therapy for ileocaecal Crohn's disease in Sweden

Clinical Drug Investigation

Volumn 15, Issue 2, 1998, Pages 123-136

  Noble, Ian ^a   Brown, Ruth ^a   Danielsson, Åke ^b   Ericsson, Karin ^c   Florén, Claes Henrik ^d   Hertzman, Peter ^c   Löfberg, Robert ^e  

^a MEDTAP International   (United Kingdom)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DECISION MAKING; DOUBLE BLIND PROCEDURE; DRUG COST; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SURGERY; TREATMENT OUTCOME; VALIDATION PROCESS; WELLBEING;

EID: 0031910685     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199815020-00006     Document Type: Article

References (45)

1. Lichtenstein GR. Medical therapies for inflammatory bowel disease. Curr Opin Gastroenterol 1993; 9: 588-99
2. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. JAMA 1932; 99: 1323-9
3. Farmer R, Hawk W, Turnhull R. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975; 86: 627-35
4. Mekhjian H, Switz D, Melnyk C, et al. Clinical features and natural history of Crohn's disease. Gastroenterology 1979; 77: 898-906
5. Lapidus A, Bernell O, Hellers G, et al. Crohn's colitis in Stockholm County. Gut. In press
6. DaCosta L. What is inflammatory bowel disease? Can J Gastroenterol 1993; 7: 503-8
7. Ekhom A, Helmick C, Zack M, et al. The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology 1991; 100: 350-8
8. Mourn B, Vatn MH, Ekhom A, et al. The incidence of Crohn's disease in four counties in Southeast Norway, 1990-93: a prospective population-based study. Scand J Gastroenterol 1996; 31: 355-361
9. Löfberg R. New steroids for inflammatory bowel disease. Inflamm Bowel Dis 1995; 1: 135-41
10. Singleton J, Law D, Kelley M, et al. National cooperative Crohn's disease study: adverse reactions to study drugs. Gastroenterology 1979; 77: 870-82
11. Brogden R, McTavish D. Budesonide: an updated review of its pharmacological properties and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44: 375-407
12. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of hudesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5
13. Brattsand R. Concepts of topical steroid therapy. Res Clin Forums 1996: 18: 57-65
14. Agenoft L, Pedersen S. Effects of long term treatment with inhaled corticosteroids on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373-81
15. Möller C, Sandahl G, Henricson KA, et al. An open long-term study of hudesonide in children with perennial rhinitis. Clin Exp Allergy 1990; 20(1 Suppl.): 101
16. Möller C, Ek L, Svensson IL. Nasal budesonide to children for 5 years. Allergy Clin Immunol News 1994; 6(2 Suppl.): 427
17. Greenberg G, Feagan B, Martin F, et al. Oral hudesonide for active Crohn's disease. N Engl J Med 1994; 331: 836-41
18. Campieri M, Ferguson A, Doe W, et al. Oral hudesonide is as effective as oral prednisolone in active Crohn's disease. Gut 1997; 41: 209-14
19. Thomsen OO, Cortot A, Jewell D, et al. Budesonide CIR is more effective than mesalazine in active Crohn's disease. A 16 week, international randomized, double-blind multicentre trial. Gastroenterology 1997; 112 (4 Suppl.): A1104
20. Greenherg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study (The Canadian Inflammatory Bowel Disease Group). Gastroenterology 1996; 110: 45-51
21. Löfberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut 1996; 39: 82-6
22. Fergusson A, Campieri M, Doe W, et al. Oral hudesonide as maintenance therapy in Crohn's disease - results of a 12 months study. Aliment Pharmacol Ther. In press
23. Feagan B, Greenherg GR, Löfberg R, et al. Budesonide controlled ileal release prolongs remission in Crohn's disease (CD): A pooled analysis. Gastroenterology 1997; 112 (4 Suppl.): A970
24. Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334: 841-8
25. Gendre J-P, Mary J-Y, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. Gastroenterology 1993; 104: 435-9
26. Sahmoud T, Mary JY. Mesalazine as a maintenance treatment in Crohn's disease: is it the long awaited solution? Gut 1977; 40: 284-5
27. Sutherland LR. Maintenance therapy for inflammatory bowel diseases: what really works? Can J Gastroenterol 1997; 11: 261-4
28. SMLTREE, Version 2.2, Hollenberg J, Roslyn, NY, USA
29. Data, Version 3.0, TreeAge Software Inc., Williamstown, MA, USA
30. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38
31. Fineberg H. Decision trees: construction, uses and limits. Bull Cancer 1980; 67: 395-404
32. Salomon P, Kornbluth A, Aisenberg J, et al. How effective are current drugs for Crohn's disease? A meta-analysis. J Clin Gastroenterol 1992; 14: 211-5
33. Best W, Becktel J, Singleton J, et al. Development of a Crohn's disease activity index. Gastroenterology 1976; 70: 439-44
34. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706
35. Winslet MC, Keighley MRB. Surgery for Crohn's disease of the colon. In: Allan RN, Keighley MRB. Alexander-Williams J, Hawkins C, editors. Inflammatory bowel disease. London: Churchill Livingstone, 1990: 473-82
36. Lapidus A, Bohman L, Löfberg R, et al. The cost of Crohn's disease in Sweden. Gut 1996; 39 (3 Suppl.): A95
37. FASS 1996. Läkemedel i Sverige. Stockholm: Linfo, 1996
38. Nilsson CA, Carling K, Erlö CK, et al. Vårdkostnader 1994. DRG-jämförelser av sjukhus och kliniker. Spri rapport 437 (Swedish Institute for Health Services Development). Stockholm: Spris Förlag, 1997
39. Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992; 14: 309-17
40. Silverstein MD, Loftus Jr EV, Sandborn WJ, et al. Cost of care of Crohn's disease in the community setting. Gastroenterology 1997; 112(4 Suppl.): A1093
41. Trallori G, Messori A. Drug treatments for maintaining remission in Crohn's disease. A lifetime cost-utility analysis. Pharmacoeconomics 1997; 11: 444-53
42. Johannesson M, Jönsson B. Ekonomisk utvärdering av läkemedel (Economic assessment of drugs). Stockholm: SNS Förlag, 1993
43. Erhardt L, Ball S, Andersson F, et al. Cost effectiveness in the treatment of heart failure with ramipiril. A Swedish substudy of the AIRE study. Pharmacoeconomics 1997; 12 (2 Pt 2): 256-66
44. Tengs TO, Adams ME, Pliskin JS, et al. Five hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15: 369-90
45. Statistics Sweden. Statistical Yearbook of Sweden 1997. Vol. 83. Stockholm: Nordstedts Tryckeri AB, 1996